These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 23667165)

  • 1. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
    Callahan MK; Wolchok JD
    J Leukoc Biol; 2013 Jul; 94(1):41-53. PubMed ID: 23667165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
    Intlekofer AM; Thompson CB
    J Leukoc Biol; 2013 Jul; 94(1):25-39. PubMed ID: 23625198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nobel goes to immune checkpoint-Innovative cancer treatment by immunotherapy.
    Li J; Dong C
    Sci China Life Sci; 2018 Nov; 61(11):1445-1450. PubMed ID: 30377902
    [No Abstract]   [Full Text] [Related]  

  • 8. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
    Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
    J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting T Cell Co-receptors for Cancer Therapy.
    Callahan MK; Postow MA; Wolchok JD
    Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Pennock GK; Chow LQ
    Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
    Skafi N; Fayyad-Kazan M; Badran B
    Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
    Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
    Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
    Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
    Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
    Brunner-Weinzierl MC; Rudd CE
    Front Immunol; 2018; 9():2737. PubMed ID: 30542345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
    Zappasodi R; Merghoub T; Wolchok JD
    Cancer Cell; 2018 Apr; 33(4):581-598. PubMed ID: 29634946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
    Hahn AW; Gill DM; Pal SK; Agarwal N
    Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.